A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants with Stage III Unresectable NSCLC - PACIFIC-8

Study identifier:D9075C00001

ClinicalTrials.gov identifier:NCT05211895

EudraCT identifier:2021-004327-32

CTIS identifier:2023-506891-28-00

Recruiting

Official Title

A Phase III, Randomised, Double-blind, Placebo-controlled, Multicentre, International Study of Durvalumab plus Domvanalimab(AB154) in Participants with Locally Advanced (Stage III), Unresectable Non-small Cell Lung Cancer Whose Disease has not Progressed Following Definitive Platinum-based Concurrent Chemoradiation Therapy

Medical condition

Non-small Cell Lung Cancer

Phase

Phase 3

Healthy volunteers

No

Study drug

Durvalumab, Domvanalimab

Sex

All

Estimated Enrollment

860

Study type

Interventional

Age

18 Years - n/a

Date

Study Start Date: 18 Feb 2022
Estimated Primary Completion Date: 27 Jun 2028
Estimated Study Completion Date: 30 Aug 2030

Study design

Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Jan 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

Arcus Biosciences Inc

Inclusion and exclusion criteria